Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
about
The use of putative placebo in active control trials: two applications in a regulatory settingClinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancerCisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer.A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.Breast cancer (metastatic).Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeNEO adjuvant chemotherapy in breast cancer: What have we learned so far?Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.Cardiovascular toxicities from systemic breast cancer therapy.Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.Chemotherapy of advanced breast cancer: outcome and prognostic factors.US Food and Drug Administration approval overview in metastatic breast cancerDose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracilSecond-line treatment of postmenopausal women with advanced breast carcinoma.A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerMulticenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safetySequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancerActivity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancerEfficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.Reversed lipid-based nanoparticles dispersed in oil for malignant tumor treatment via intratumoral injection.Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization.
P2860
Q28195333-14B2811B-C9ED-4EF1-989F-E3B758EB0675Q30670717-6E2E58B8-023E-4F9B-AC98-02EF76622CDDQ33244593-AE0E0657-55B4-43D0-906F-2945D12F1161Q33330720-DFE63088-164D-4419-B5B1-ACE69F1E0C2DQ33332712-AA4AC88D-EBCF-4897-ABA8-725D887A5B93Q33334493-CE2679C9-A3E3-4E92-BD0E-72C61E1BFBE2Q33383216-195FEB6D-C0F2-4AF7-BF0B-427EC7C98A20Q33395356-97A67DB2-E478-4F25-A131-4277D0F8ACB5Q33448016-1FF04251-580E-47E6-866F-4616D60F81D8Q33488311-6C2B87A9-87A8-4AAF-BE42-875D61A2A3BBQ33503243-F60B4D79-9AB6-4FE7-A42C-6FF26FAE4643Q33710233-B674813B-F285-4E19-BC37-2F04EAD6B762Q34138174-3823EDFD-F64E-4170-B931-F605D2CBBB0CQ34215077-F41960C8-63CF-49B2-B956-47CA232F3F69Q34630349-721C38F9-EEF9-4F8E-9948-307C5140BD5CQ35037923-EFED2962-29A3-411E-83D6-C5B4E09AD09BQ35977908-08997CF8-3DCC-4225-9BA5-CAFB088F5446Q36058269-8C8D7A45-F25A-41BA-830C-2095FF1C004BQ36217005-69FC7A68-7367-45D0-B4C0-152A4242F9CCQ36448699-EE839646-2227-47F1-BA99-0CC2D5DFE0C7Q36624187-0606A5A9-E7C3-41D3-844C-95C3DC496031Q36625974-88D80261-E0F1-4691-B25E-8DF61CA9D802Q36644194-92D98C4A-4F9B-4554-A5FD-AE0663A753E5Q36673766-C8304685-55E6-4841-8426-9F316484A8F9Q36695861-A6C04194-6CA1-4800-B884-04C265EC8494Q36696923-EA05FB04-924A-4B7E-9A26-40D44C5A8F58Q37239820-70304C7E-02C3-41EE-AA4D-0EC283386D1FQ37338228-7173DFC3-1B6A-47A8-9FB4-498488932020Q40458598-2B42FB98-5AD4-451E-9A13-315B2D1743C6Q43997341-F344334C-4FE2-4566-A20F-5B23D9114ABBQ44068917-1F035C87-6C9C-4CAD-A9DC-F310DE3E4B7CQ44104081-41C1946A-F06E-49A1-A556-C7AAD764D7F6Q44180975-DDDB0D6F-3A83-4E07-8CE9-11F7B88184CEQ44325856-08107EC9-1D79-4990-A35B-40ED364018B0Q44817374-0F761F7A-B2A4-4A84-A59F-D71AC291A666Q45190962-7A539737-07DE-45DB-B2ED-595D71F8D1DCQ45952575-66CB1030-D5A9-48CA-BA8A-3E26F4BBA2B4Q46567991-155CDDE2-4296-48FC-B328-E77271756F3CQ48792087-F0D66360-8DF5-43D2-9645-7FBE8A3D1CB3Q51825395-637515C0-25A0-43FC-9C73-6E8014D3EB0B
P2860
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@ast
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@en
type
label
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@ast
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@en
prefLabel
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@ast
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@en
P2093
P2860
P356
P1476
Chemotherapy and survival in a ...... bicin in Cooper type regimens.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1993.146
P407
P577
1993-04-01T00:00:00Z
P5875
P6179
1017458293